Cardiovascular Risk Factor
Conditions
Brief summary
The study Sponsor, Heart Force Medical Inc. (HFM), has developed a patented medical device called the SPhENo-CardiographTM. The SPhENo-Cardiograph™ provides a non-invasive assessment of the electro-mechanical function of the heart. The electrocardiograph (ECG) represents the waveform of the electrical stimulus to the cardiac muscle. The mechanical actions of the electrical potentials delivered in the ECG are revealed as the seismocardiograph (SCG). The SCG represents the changes in acceleration of the heart during the cardiac cycle. The SCG waveform reflects the ultra-low frequency vibrations of cardiac contraction. These low frequency vibrations are transmitted through the sternum. Using the point of initiation of ventricular contraction on the ECG, the Q wave, with fiduciary points on the synchronous seismocardiograph, it is possible to determine timing events of the cardiac cycle. The timing events of the cardiac cycle during systole are referred to as Systolic Timing Intervals (STI) and comprise the Pre-Ejection Period (PEP) and the Left Ventricular Ejection Time (LVET). The PEP is the time from the Q wave to the Aortic valve opening. The Left Ventricular Eject Time (LVET) is the time between the Aortic Valve opening and closing. The ratio of PEP/LVET in individuals with established heart disease is \> 0.42. It is based on the formula described by Dr Arnold Weissler and first published in Circulation in 1968 (Weissler et al,1968). Weissler et al showed that the PEP/LVET ratio \>0.42 are indicative of a lengthening of the PEP with some marginal shortening of the LVET. This is indicative of pathology associated with the coronary circulation (Ahmed et al, 1972;). This ratio can then be used as part of a non-invasive quantitative assessment of cardiac performance (Lewis et al 1977). Using the SPhENo-CardiographTM, HFM has developed an algorithm to assess heart health that otherwise requires a number of technologies; stethoscope, ECG and Carotid pulse tracing to identify the dicrotic notch or Aortic Valve closure.
Interventions
DEVICESPhENo-Cardiograph
SPhENo-Cardiograph
Sponsors
Heart Force Medical Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Able to understand the informed consent document * Willing to participate in study * Ambulatory volunteer
Exclusion criteria
* Individuals with visible scar(s) or deformity in the test area of the chest * Non-ambulatory subjects * Previously diagnosed with life-threatening condition (e.g. cancer) * Known or diagnosed psychiatric condition * Enrolled in a concurrent study or trial * Exercised excessively within the last 4 hours (prior to study visit) * Consumption of caffeine containing drinks within the previous 4 hours * Unwilling to sign Informed Consent * Female subjects who are pregnant, suspected or planning to become pregnant or breast-feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation coefficient ≥0.8 between STI ratio values determined by the SPhENo-Cardiograph™ and an echocardiograph | 1 day |
| Correlation coefficient ≥0.8 between PEP values determined by the SPhENo-Cardiograph™ and an echocardiograph | 1 day |
| Correlation coefficient ≥0.8 between LVET values determined by the SPhENo-Cardiograph™ and an echocardiograph | 1 day |
| Correlation coefficient ≥0.8 between heart rate values determined by the SPhENo-Cardiograph™ and an echocardiograph | 1 day |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation coefficient ≥0.8 between heart rate values determined by the SPhENo-Cardiograph™ and a manual analysis | 1 day | — |
| Safety and tolerability assessed by Adverse event collection | 1 day | Adverse event collection |
| Subject questionnaire | 1 day | Questionnaire to evaluate relevance of device from subject's perspective; data to be analyzed qualitatively |
| Correlation coefficient ≥0.8 between STI ratio values determined by the SPhENo-Cardiograph™ and a manual analysis | 1 day | — |
| Correlation coefficient ≥0.8 between PEP values determined by the SPhENo-Cardiograph™ and a manual analysis | 1 day | — |
| Correlation coefficient ≥0.8 between LVET values determined by the SPhENo-Cardiograph™ and a manual analysis | 1 day | — |
Countries
Canada
Outcome results
None listed